When accessing the CDB site through an internal Novo Nordisk IP address, you will see "Your Location" as NN Internal instead of a country. This only applies to internal NN IP addresses. Thank you for your patience while the development team is upgrading this feature.

Your Location: USA

Help Join the Cause Submit Data

Bookmark and Share

Diabetes Pandemic

Diabetes Prevalence

Diabetes prevalence is increasing in every country in the world, and the toll is climbing in terms of human lives as well as the costs to society.

  • It is predicted that in 2010, 285 million people, or approximately 6.4% of the world’s adult population, will live with diabetes.
  • By 2030 this number is expected to grow to 439 million.1
  • Worldwide, only half of all people with diabetes are diagnosed.2

People with type 2 diabetes may remain undiagnosed for several years, so a significant number already have serious medical complications associated with hyperglycaemia3 by the time they see a doctor.4 Due to its chronic, progressive nature, the severity of related complications and the medical treatment required to treat advanced stages, diabetes is a costly disease.

In the United States alone, the direct and indirect cost of diabetes totals $218 billion (USD) per year. In developing countries where diabetes incidence and diabetes prevalence are among the highest5 mechanisms for financing healthcare are poor and people with diabetes and their families must bear almost the entire cost of diabetes treatment.

Change is Essential

Unless diabetes prevention, early diagnosis, and treatment are drastically improved, the world faces a global pandemic. In the developing world, type 2 diabetes may account for more than 95% of all diabetes cases.3 An overall aging population, sedentary occupations resulting in reduced physical activity and unhealthy eating patterns leading to obesity1 are all contributing to dramatic increases in the global incidence of type 2 diabetes and the intensified need to focus on how to manage diabetes and the associated costs.

In the United States, the obesity epidemic is contributing to the growing prevalence and cost of diabetes. Estimates reveal that the number of Americans with diabetes will increase by over 80% to 44 million by 2034, with direct health care costs increasing from $116 billion (USD) to $336 billion a year. Learn more about the impact of diabetes on the United States economy and society-at-large in this article from Forbes magazine.

Providing good diabetes care for a national population requires coordination and responsibility across all levels of society. From the person with diabetes to healthcare organisations and national plans from which care is delivered, supporting policies and financing frameworks have a great impact on society’s ability to prevent, diagnose, and change diabetes. Read about the impact of the diabetes pandemic around the world in the Changing Diabetes Briefing Books.

Novo Nordisk’s overarching ambition is to defeat diabetes. Changing Diabetes Barometer is just one initiative that is part of the Changing Diabetes® global campaign which focuses on curbing the diabetes pandemic and promoting universal access to the best quality of diabetes care.

Return To Top

See How Your Country Measures Up

Get diabetes data in four key areas: Quality of Care, Prevalence of Diabetes, Cost of Diabetes, and Access to Care

Diabetes Data

Join the Cause

Answer the call to measure, share, and improve

Join the Cause

Read About the Global Impact of Diabetes

Learn about the human and economic impact of diabetes in other countries

Briefing Books

References:
1. International Diabetes Federation. Diabetes and impaired glucose tolerance. In: The Diabetes Atlas. Fourth Edition. Brussels: International Diabetes Federation; 2009.
2. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes and cardiovascular diseases: full text. Eur Heart J. 2007. doi: 10.1093/eurheartj/ehl261
3. Stratton IM, Adler AI, Neil HA et al., for the United Kingdom Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258): 405-412.
4. International Diabetes Federation. Morbidity and mortality. In: The Diabetes Atlas. Fourth Edition Brussels: International Diabetes Federation; 2009
5. Dall T, Zhang Y, Chen Y, et al. The Economic Burden of Diabetes. Health Affairs.29, NO. 2 (2010).

Return To Top